FAEGX | RGAGX | FAEGX / RGAGX | |
Total Expense Ratio | 1.17 | 0.30 | 390% |
Annual Report Gross Expense Ratio | 1.17 | 0.30 | 390% |
Fund Existence | 33 years | 16 years | - |
Gain YTD | 0.901 | 5.137 | 18% |
Front Load | 4% | N/A | - |
Min. Initial Investment | 0 | 250 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 11.6B | 306B | 4% |
Annual Yield % from dividends | 0.00 | 0.65 | - |
Returns for 1 year | -5.37 | 6.85 | -78% |
Returns for 3 years | 49.96 | 52.96 | 94% |
Returns for 5 years | 39.93 | 46.07 | 87% |
Returns for 10 years | 91.64 | 72.70 | 126% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
JHI | 13.49 | 0.02 | +0.15% |
John Hancock Investors Trust Capital Stock | |||
EPV | 27.82 | N/A | N/A |
ProShares UltraShort FTSE Europe | |||
XBI | 82.38 | -0.28 | -0.34% |
SPDR® S&P Biotech ETF | |||
SPXX | 16.93 | -0.09 | -0.53% |
Nuveen S&P 500 Dynamic Overwrite Fund | |||
DVYE | 27.87 | -0.33 | -1.17% |
iShares Emerging Markets Dividend ETF |